

## Current report

### according to ASF Regulation no. 5/2018

Report date:	<b>17.08.2023</b>
Name of issuer:	Farmaceutica REMEDIA S.A.
Registered office:	Deva, no. 2, Nicolae Bălcescu Blvd
Tel/ fax no:	+40 254 22 32 60 / +40 254 22 61 97
ORC no:	2115198
Trade Registry no:	J20 / 700 / 1991
Subscribed and paid-in capital:	LEI 9.548.082
Regulated market:	Bucharest Stock Exchange, Standard Category

### Important events to report:

#### RELEASE

The Board of Directors of Farmaceutica REMEDIA S.A. informs that the Report for the 1st Semester of 2023 - the full version - is available on its own website <http://www.remEDIA.ro/en/investors-2-2/company-financials/> and in the link from the IRIS platform, below.

During 01.01.2023 – 30.06.2023, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-June 2023 (Lei)	Realisations Jan-June 2022 (Lei)**	Evolution 2023/2022 (%)
1.	Net sales of goods *	278.221.682	255.335.849	8,2%
2.	Other operating revenues	6.983.302	4.534.167	35,1%
3.	Total operating income	285.204.984	259.870.017	8,9%
4.	Total operational costs *	280.947.439	255.260.227	9,1%
5.	Operating result	4.257.544	4.609.790	-8,3%
6.	Financial result	309.485	-160.729	151,9%
7.	Gross result	4.567.030	4.449.060	2,6%

\* Including trade discounts granted/received

The economic - financial indicators on 30.06.2023 are presented in the following table:

<b>LIQUIDITY AND WORKING CAPITAL</b>	<b>Farmaceutica REMEDIA SA</b>	<b>Farmaceutica REMEDIA Distribution &amp; Logistics SRL</b>	<b>Pharma Expert Spedition SRL</b>
<b>Current liquidity (Current assets / Current debts)</b>	1,37	1,06	0,31
Current assets	15.822.364	223.849.070	678.603

Current debts	11.564.646	210.194.206	2.221.221
<b>Degree of indebtedness (Borrowed capital / Equity x 100)</b>	0	0,00%	450%
Borrowed capital	0,0%	0	680.123
Equity	48.525.174	14.155.275	150.986
<b>Turnover speed for client debit items (Average customer balance /turnover *180)</b>	67	102	39
Average customer balance	2.788.132	158.141.164	665.000
Net turnover	7.484.604	278.745.761	3.087.996
<b>Turnover speed of stocks (average stock/ net COGS)*180</b>	85	30	-
Average stock	2.237.616	42.340.912	-
COGS net	4.737.842	257.994.593	-

\*including financial leasing

**Notes:**

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR and FRDL, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of FR and FRDL there is no risk at all while for PES the indicator value indicates a risk caused by financial leasing loans. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specifics of receivables in the distribution of medicines, we consider that the value of the indicator is normal for the companies from the group, under the given conditions.

4) The value of the indicator **No. of days of storage** can be considered to be in line with the specific activity.

**Chairman of the Board of Administrators,**

**„TARUS” – Valentin Norbert TARUS e.U.**